The Genesys HTA System developed by Boston Scientific Corporation to treat menorrhagia has received approval from the US Food and Drug Administration (FDA).

The Genesys HTA System is a next-generation endometrial ablation system to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia.

The system features a smaller and lighter console, simplified set-up requirements and an enhanced graphic user interface offering step-by-step guidance through the procedure.

The system also includes upgraded technology to improve operating performance while delivering the same proven clinical therapy of the company’s current HTA Endometrial Ablation System.

The system also received CE Mark approval in January.